AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00916721
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visit 2 (first smoking-related memory reactivation session) the subject will be given 0.67 mg/kg (minimum 40 mg; maximum 80 mg) of short-acting propranolol (or placebo) rounded to the nearest 10 mg. Ninety minutes after this dose, if subject has tolerated the short-acting dose well, and if systolic blood pressure has not fallen by 10 mmHg or more to below 100 mmHg, the subject will be given oral long-acting propranolol 1 mg/kg (minimum 60 mg; maximum 120 mg) or placebo rounded to the nearest 20 mg. . If the subject tolerates the combination dose well, during treatment phase (from visit 7 to 12), both the short- and long-acting doses will be given together immediately prior to memory reactivation.
Trial: NCT04331730
Drug: AKST4290
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral AKST4290
Trial: NCT04331730
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo
Trial: NCT01466478
Drug: Ointment B: LEO 29102 2.5 mg/g ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily application, 4 weeks
Trial: NCT03073395
Drug: [68Ga]P16-093
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imaging by Positron Emission Tomography after iv injection of \[68Ga\]P16-093
Trial: NCT03904576
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT02145767
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02133014
Drug: 0.5% 5-fluorouracil normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the one hand,0.5% 5-fluorouracil normal saline directly inhibit DNA synthesis of pancreatic acinar cells which result in the synthesis of amylopsin of and trypsase is restrained.On the other hand,it can induce pancreatic cells apoptosis and alleviate pancreatic necrosis.
Trial: NCT00318201
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00049413
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02468089
Drug: GMCSF (of Granulocyte-Monocyte Colony-Stimulating Factor) .
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03729869
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of matched placebo twice a day.
Trial: NCT00883194
Drug: PRF-108
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine
Trial: NCT00883194
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRF-108 Placebo
Trial: NCT00883194
Drug: PRF-110
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00144105
Drug: TPV500mg/RTV200mgBID
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00893113
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin-matched One tablet once daily
Trial: NCT02974257
Drug: Thiamine
RxNorm normalized name: Thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiamine 500mg IV twice daily for 2 days
Trial: NCT00403117
Drug: Placebo + Inactive Marijuana (0% THC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule containing placebo was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
Trial: NCT00403117
Drug: Placebo + Active Marijuana (3.27% THC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule containing placebo was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before administration of a marijuana cigarette containing 3.27% THC (ca. 800 mg) provided by the National Institute on Drug Abuse.
Trial: NCT01707823
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00077987
Drug: SU011248
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01654562
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 40mg daily by mouth for 5 weeks (4-6 week window) followed by 5 week washout period (4-6 week window).
Trial: NCT01997567
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of saline with epinephrine 1:200,000 (150 mcg) (total 30 ml)
Trial: NCT01115946
Drug: ASP1585
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03774745
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to placebo receive treatment starting day 2.
Trial: NCT02268565
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pill that looks like aspirin without the effects of aspirin
Trial: NCT03864913
Drug: Testosterone injection
RxNorm normalized name: testosterone Injection
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SQ or IM testosterone injections for pubertal induction of transgender male adolescents. Increasing doses per protocol at 3 month and 6 month follow up.
Trial: NCT02778880
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03074162
Drug: Diclofenac Sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: twice daily
Trial: NCT00890682
Drug: SKY0402
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration of 8cc SKY0402
Trial: NCT00592150
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion for 3 hours
Trial: NCT00849693
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules identical in appearance, color, taste, and smell to study drug, orally, once daily for 10 weeks (acute treatment phase)
Trial: NCT00849693
Drug: fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 milligram (mg) orally, once daily for 10 weeks (acute treatment phase) and 20-40 mg orally, once daily for additional 6 months (extension phase)
Trial: NCT00890682
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration of 8cc Placebo
Trial: NCT02952547
Drug: DWJ1366 Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03229746
Drug: azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dose 100mg daily for at least 3 weeks
Trial: NCT01586663
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This patients will keep there drug treatment and will receive their splints on the end of the study.
Trial: NCT03690414
Drug: Experimental BHVI2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental BHVI2 eye drops
Trial: NCT02928393
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to basmisanil immediate-release granules will be given orally twice daily for 90 days.
Trial: NCT00359814
Drug: Mycophenolatmofetile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mycophenolatmofetile administration: was started with 250 mg/daily at day 1, the start dose was increased about 250 mg/daily every week till 2 g/daily
Trial: NCT04594408
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mL of 1:1000 mixed into irrigation bag.
Trial: NCT04594408
Drug: Epinephrine and Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mL of 1:1000 epinephrine mixed into irrigation bag, and 1 g tranexamic acid x 1 dose to be administered intraoperatively.
Trial: NCT02369978
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two capsules of matching placebo (contaning Magnesium stearate and cellulose) B.I.D
Trial: NCT03802422
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided hydrodissection with 3cc 0.9% normal saline between carpal tunnel and median nerve.
Trial: NCT04635527
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: before surgery placebo intravenous injection Q2W,after surgery placebo intravenous injection Q4W
Trial: NCT02393599
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg 2 times per day from Day 3 to 9 and one time on Day 10
Trial: NCT00718861
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00718861
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04618497
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each patient in the ketorolac group will receive one dose of 30mg intramuscular ketorolac injected at gluteal muscle by nursing staff as usual daily practice.
Trial: NCT04616430
Drug: Topical endoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical solution
Trial: NCT04616430
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical
Trial: NCT02296229
Drug: androgen deprivation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: up to 9 months at the discretion of the treating physician
Trial: NCT05169450
Drug: Ginaton
RxNorm normalized name: Genaton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive intravenously administered Ginaton, combined with guidelines-based standard care.
Trial: NCT00756977
Drug: BLI850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multi-dose preparation for oral administration prior to colonoscopy
Trial: NCT04115397
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treating seropositive individuals with musculoskeletal symptoms with one infusion zolendronic acid as compared to placebo
Trial: NCT04115397
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01558089
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: according to SmPC and clinical practice
Trial: NCT02571179
Drug: intranasal fentanyl 50 microg dose up to 250 microg
RxNorm normalized name: fentaNYL Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: When contraction pain was ≥ 5/10 (numerical rating scale 0= no pain, 10= worst pain), the parturient was given a intranasal fentanyl 50 µg dose. After 15 minutes, if contraction pain was still ≥ 5/10, a second 50 µg intranasal dose was administered. Fentanyl was administered every 15 minute until contraction pain decreased to less than 5/10 or until the maximum fentanyl dose of 250 µg was administered.
Trial: NCT03465735
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant therapy will be decided by physician and patient.
Trial: NCT01884285
Drug: Part A: AZD8186 monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial schedule will use intermittent dosing of AZD8186. Dose, frequency and schedule in subsequent cohorts may be modified in response to safety, tolerability, pharmacokinetic and preclinical data.
Trial: NCT01884285
Drug: Part B: AZD8186 monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B will be at a dose(s) and schedule(s) at or below from Part A
Trial: NCT01884285
Drug: Part D1: AZD2014 combination with AZD8186
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose \& schedule finding of AZD8186 in combination with AZD2014
Trial: NCT03766997
Drug: Hydrocortisone Butyrate 0.1% Cream
RxNorm normalized name: HYDROCORTISONE BUTYRATE 0.1% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical use
Trial: NCT02112604
Drug: Sedatives and muscle relaxants given in the ICU
RxNorm normalized name: MUSCLE RELAXANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the ICU are administered sedatives, anesthetics, opiods, anti-pyschotics and neuromuscular blocking agents as part of routine care. We hypothesize that the use of these drugs is associated with sleep-disordered breathing following extubation. We will collect the drug doses from the patient's chart.
Trial: NCT00192517
Drug: MEDI-522
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg (for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0)
Trial: NCT04064684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients will be treated with normal saline.The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit. The maximum length of treatment will be 10 days.
Trial: NCT03567499
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules to match active 100 mg and 200 mg dose strength will be available and to be taken as single or multiple capsules orally along with water depending on the number of active capsules to blind.
Trial: NCT03117049
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
Trial: NCT00195559
Drug: Levonorgestrel/Ethinyl Estradiol
RxNorm normalized name: levonorgestrel/ethinyl estradiol 0.1 mg-20 mcg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01713400
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of sterile saline (identical volume to that of ustekinumab) administered via the identical route and schedule as ustekinumab.
Trial: NCT00121810
Drug: mycophenolate mofetil [CellCept]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0-1.5 g oral dose twice daily
Trial: NCT00121810
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT00121810
Drug: Calcineurin inhibitors
RxNorm normalized name: Calcineurin inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT00365976
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nightly over duration of double blind study phase
Trial: NCT00828867
Drug: 100 mg GSK investigational drug
RxNorm normalized name: INVESTIGATIONAL THROMBOLYTIC DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00828867
Drug: 200 mg GSK investigational drug
RxNorm normalized name: INVESTIGATIONAL THROMBOLYTIC DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00828867
Drug: 400 mg GSK investigational drug
RxNorm normalized name: INVESTIGATIONAL THROMBOLYTIC DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00828867
Drug: 800 mg GSK investigational drug
RxNorm normalized name: INVESTIGATIONAL THROMBOLYTIC DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00828867
Drug: 2000 mg GSK investigational drug
RxNorm normalized name: INVESTIGATIONAL THROMBOLYTIC DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00828867
Drug: 1500 mg GSK investigational drug
RxNorm normalized name: INVESTIGATIONAL THROMBOLYTIC DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00828867
Drug: 800mg fed GSK investigational drug
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00828867
Drug: 3000mg GSK investigational drug
RxNorm normalized name: INVESTIGATIONAL THROMBOLYTIC DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00828867
Drug: 4000mg GSK investigational drug
RxNorm normalized name: INVESTIGATIONAL THROMBOLYTIC DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04676139
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine 10 mg capsules once daily for 12 months
Trial: NCT04676139
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for 12 months
Trial: NCT00053820
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00073593
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: : Per institutional practice, at 1.5-3.5 mg/kg (200-400 U/kg) IV bolus to achieve a target ACT of \>300 s followed by weight-adjusted boluses as needed during surgery to achieve/maintain the target ACT. Batches from hospital stock.
Trial: NCT06671431
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with or without radiotherapy
Trial: NCT00308295
Drug: matched placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00972998
Drug: Phenyephrine
RxNorm normalized name: CTM 4/IBUPRO 200/PHENYEPHRINE 10MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenyephrine coated suppositories
Trial: NCT02014116
Drug: LY3009120 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT01970033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Run in period ：oral tablets of Placebo twice daily for 2 weeks~* Phase A : oral tablets of Placebo twice daily for 24 weeks~* Phase B : SP2086 50 mg b.i.d or SP2086 100 mg q.d. for 28 weeks
Trial: NCT01970033
Drug: SP2086 50 mg b.i.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Run-in period: placebo twice daily for 2 weeks~* Phase A:SP2086 50 mg b.i.d for 24 weeks~* Phase B:SP2086 50 mg b.i.d for 28 weeks
Trial: NCT01970033
Drug: SP2086 100 mg q.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Run-in period:placebo twice daily for 2 weeks~* Phase A: SP2086 100 mg q.d. for 24 weeks~* Phase B: SP2086 100 mg q.d. for 28 weeks
Trial: NCT03892772
Drug: SAS0421a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment will be given for 3 days
Trial: NCT03892772
Drug: SAS0421b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment will be given for 3 days
Trial: NCT03892772
Drug: SAS0421c
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment will be given for 3 days
Trial: NCT03892772
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo will be given for 3 days
Trial: NCT03279978
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04215991
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care administered will be selected by the investigator based on the suspected or confirmed pathogen(s) for the infection in accordance with local standards.
Trial: NCT01247818
Drug: PH-10 (0.002% Rose Bengal)
RxNorm normalized name: prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
Trial: NCT01247818
Drug: PH-10 (0.005% Rose Bengal)
RxNorm normalized name: prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
Trial: NCT01247818
Drug: PH-10 (0.01% Rose Bengal)
RxNorm normalized name: prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
Trial: NCT01247818
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PH-10 vehicle will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
Trial: NCT00400491
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule twice a week, identical to the cholecalciferol capsules
Trial: NCT02601001
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets
Trial: NCT01225393
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Stable dose if not on leflunomide
Trial: NCT01225393
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous repeating dose
Trial: NCT01841008
Drug: Placebo : Diprobase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment (tacrolimus or placebo) will be delivered to the patient by the hospital pharmacy and should be applied twice per week (3 or 4 days apart) for 24 weeks.
Trial: NCT01330381
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching oral solution or oral tablets given once daily
Trial: NCT02162745
Drug: Hypertonic solution (NaCl 3%)
RxNorm normalized name: Hypertonic solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01369719
Drug: osveral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: receive 20 mg/kg daily orally
Trial: NCT01257126
Drug: diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes